The global Nystatin API market is entering a phase of stable and strategically significant growth, driven by rising fungal infection prevalence and expanding pharmaceutical production capacity worldwide. The market, valued at USD 32 million in 2024, is projected to reach USD 41.1 million by 2031, progressing at a CAGR of 3.8%. As the demand for safe, effective antifungal therapies grows,...